Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

Blood Cancer J. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Randomized Controlled Trial
  • Validation Study

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Azacitidine / analogs & derivatives
  • Azacitidine / therapeutic use
  • Decitabine
  • Drug Resistance, Neoplasm / drug effects
  • Glycine / analogs & derivatives*
  • Glycine / therapeutic use
  • Humans
  • Kaplan-Meier Estimate
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / mortality
  • Prognosis
  • Sulfones / therapeutic use*
  • Treatment Outcome*

Substances

  • Antineoplastic Agents
  • Sulfones
  • ON 01910
  • Decitabine
  • Azacitidine
  • Glycine